Change Notice: Any information related to Prostate-Specific Antigen (PSA) in the following guideline may have been revised in the American Urological Association's (AUA) PSA Best Practice Statement: 2009 Update. In the case of any discrepency in recommendations between guidelines pertaining to PSA, please refer to the AUA's PSA Best Practice Statement: 2009 Update for the latest AUA recommendation regarding PSA testing.
Erectile Dysfunction Erectile Dysfunction Guideline Update Panel Members: Drogo K. Montague, M.D., Co-chair Jonathan P. Jarow, M.D., Co-chair Gregory A. Broderick, M.D. Roger R. Dmochowski, M.D. Jeremy P.W. Heaton, M.D. Tom F. Lue, M.D. Aaron J. Milbank, M.D. Ajay Nehra, M.D. Ira D. Sharlip, M.D. Consultants: Hanan S. Bell, Ph.D. Patrick M. Florer Diann D. Glickman, PharmD AUA Staff: Kirsten H. Aquino Edith M. Budd Michael A. Folmer Suzanne B. Pope Carol R. Schwartz
The Management of Erectile Dysfunction: An Update ysfunction Guideline June 2007: In July 2005, the U.S. Food and Drug Administration notified healthcare professionals of updated labeling for Cialis, Levitra and Viagra to reflect a small number of post-marketing reports of sudden vision loss, attributed to NAION (non arteritic ischemic optic neuropathy), a condition where blood flow is blocked to the optic nerve. FDA advises patients to stop taking these medicines and call a doctor or healthcare provider right away if they experience sudden or decreased vision loss in one or both eyes. At this time, it is not possible to determine whether these oral medicines for erectile dysfunction were the cause of the loss of eyesight or whether the problem is related to other factors such as high blood pressure or diabetes, or to a combination of these problems.